Found 3 articles
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022
Orchestra BioMed™, Inc. announced the presentation of positive long-term clinical results from the MODERATO II Control Patients Crossover Extension Study of BackBeat Cardiac Neuromodulation Therapy™ at the Transcatheter Cardiovascular Therapeutics 2022 annual conference being held in Boston, MA.
11/8/2021The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT™ on Isolated Systolic Hypertension and Pulse Pressure
Orchestra BioMed™, Inc. today announced multiple presentations of long-term clinical results and ISH subgroup data from the MODERATO II study of BackBeat Cardiac Neuromodulation Therapy at the annual conference being held in-person in Orlando, Florida, and virtually from November 4 – 6, 2021.